Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Schedule of Total Segment Net Loss to Consolidated Net Loss

The following table presents reportable segment profit and loss, including significant expense categories, attributable to the Company's reportable segment for the periods presented:

	Three Months Ended March 31,
	2025			2024
Clinical	$	6,050		$	5,751
CMC		6,393			4,226
Other research and development expense (1)		2,236			3,426
Personnel expense - R&D		5,701			4,362
Personnel expense - G&A		2,231			1,815
Stock-based compensation expense		1,857			1,691
Administrative & facilities expense (2)		3,221			3,074
Interest income		(1,117	)		(2,374	)
Interest expense		1,405			1,325
Other expense, net		62			51
Net loss	$	28,039		$	23,347

(1) Other research and development expenses primarily consist of consulting, regulatory support, toxicology, sponsored research costs, and other research and development activities.

(2) Administrative & facilities expense primarily consists of facilities expenses, depreciation expense, legal costs, insurance, consulting, and other administrative costs.